4 Week In-Use Study Evaluating How Well-Tolerated a Skin Care Product Is on Adults With Facial Redness

Rosacea Clinical Trial

Official title:

4 Week In-Use Study Evaluating the Tolerability of a Skin Care Product on Adults With Rosacea

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03841032
• Other study ID #: 20516
• Status: Completed
• Phase: N/A
• Start date: January 28, 2019
• Est. completion date: February 25, 2019

Study information

• Verified date: June 2019
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate if the test sunscreen skin care product will be well-tolerated and help facial redness when applied to the face after 4 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: February 25, 2019
• Est. primary completion date: February 25, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or females at least 18 years of age;

• Women of childbearing potential must agree to use adequate contraception when sexually active. Acceptable methods of contraception include, but are not limited to, (i) condoms (male or female) with or without a spermicidal agent; (ii) diaphragm or cervical cap with spermicide; (iii) intra-uterine device; (iv) hormone-based contraception (stable dose for 3 months); (v) partner vasectomy.

• Subjects with general good health as determined by a medical history form;

• Subjects with erythematotelangiectatic and/or papulopustular rosacea, at the baseline evaluation, as determined by the Investigator;

• Subjects with Fitzpatrick Skin Types I through III, as determined by the dermatologist;

• Subjects willing and capable of understanding and providing written informed consent, willing to sign a confidentiality agreement, Health Insurance Portability and Accountability Act (HIPAA) Authorization Form, and to cooperate and participate by following study requirements.

Exclusion Criteria:

• Subjects with only phymatous or ocular rosacea;

• Female subjects of child-bearing potential who test positive in a urine pregnancy test at Baseline (Visit 1), are trying to become pregnant or are nursing;

• Subjects with known allergies to any type of skin care product and/or sunscreen product and/or any ingredients in the test product;

• Subjects with any facial skin disorders which may influence results, in the opinion of the Investigator;

• Subjects with a reported history of acute or chronic dermatological (except for rosacea), uncontrolled hypertension, other medical and/or physical conditions which, in the opinion of the Investigator, interferes with evaluation of the test product or places the subject at risk;

• Subjects currently using medications or oral supplements which, in the opinion of the Investigator, may influence the outcome of the study or interfere with study observations, including rosacea treatment products;

• Individuals using or who have used any systemic medication considered to affect rosacea, specifically, but not exclusively, antibiotics or steroids, who do not agree to continue taking the specified medication at the same dose and regimen throughout the study;

• Subjects who started hormone replacement therapies (HRT) or hormones for birth control less than 3 months prior to study entry or who plan on starting, stopping, or changing doses of HRT or hormones for birth control during the study;

• Subjects with excessive facial hair that would, in the opinion of the Investigator, interfere with diagnosis or assessment of rosacea;

• Subjects who spend excessive time out in the sun;

• Subjects that have received or used an Investigational New Drug within 30 days prior to the study.

Related Conditions & MeSH terms

• Rosacea

Intervention

Drug:
• Coppertone, BAY1183345
Lotion, for 4 weeks

Locations

Country	Name	City	State
United States	The Education & Research Foundation, Inc.	Lynchburg	Virginia

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of subjects exhibiting increases in papules		Up to 4 weeks
Primary	Number of subjects exhibiting increases in erythema		Up to 4 weeks
Primary	Number of subjects exhibiting increases in dryness, telangiectasia and tactile surface roughness		Up to 4 weeks
Primary	Number of subjects exhibiting increases in any subjective irritation		Up to 4 weeks
Secondary	Change in facial redness measured by spectrophotometer		From baseline up to 4 weeks
Secondary	Change in facial redness measured by digital imaging		From baseline up to 4 weeks
Secondary	Percentages for each response to hedonic questionnaire assessing product experience		Up to 4 weeks